Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Profit Margin

Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s profit margin stands at 301.52% as of March 2026. That compares with -1805.33% in the prior-year period — up 116.7% year over year. That is above the sector sector average of 19.74%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) reported 301.52% in profit margin versus -1805.33% a year earlier — a 116.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) sits higher the its sector benchmark (19.74%) with a profit margin of 301.52%. That is roughly 1427.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 301.52% for Bellevue Life Sciences Acquisition - Warrants (09/02/2028) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s profit margin evolved across reporting periods, while the comparison chart places BLACW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.